– IriSys Chairman, CEO & Founder Gerald Yakatan, Ph.D, introduces IriSys to participants at “Asian Hub of Bio-business” Event –
San Diego, June 21, 2017 – IriSys, LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, today announced that the Company will be participating in the BIOtech Japan 2017 – 16th International Biotech & Life Sciences Exhibition and Conference to be held June 28-30 in Tokyo, Japan. The conference, which is considered the “Asian Hub of Bio-business”, is a gathering of the industry’s most cutting-edge technologies. Gerald Yakatan, Ph.D., Chairman, CEO and founder of IriSys, will be leading discussions about the Company’s expertise and its customized services for clients in Asia.
BIOtech Japan 2017 is a comprehensive three-day event that includes a conference, partnering activities, and an Academic Forum. It serves as a platform for companies in Japan and elsewhere in Asia to learn about the latest pharmaceutical technologies and innovations.
“IriSys is well-positioned to address the needs of the companies attending the BIOtech Japan 2017 conference,” said Gerald Yakatan, Ph.D., Chairman, CEO and founder of the Company. “Our main business includes formulation development, dosage form research and development, FDA regulatory assistance, and manufacturing of both clinical supplies and commercial specialty pharmaceuticals. We have experience with drugs of various classes and physicochemical properties and work closely with our clients through each stage of research and development.”
IriSys’ ongoing outreach efforts in Asia included participation in the CPhI Japan conference in Tokyo this past April. “IriSys has an excellent reputation for providing customized services to international companies seeking to take new drug products through the FDA regulatory process,” Yakatan noted. “We have successfully assisted companies in Japan, China, and Korea. Our regulatory support services range from strategic planning and attendance at FDA meetings to preparation and translations of regulatory documents.”
IriSys was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specializing in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, and strategic consulting related to the drug development process. IriSys’ custom approach to drug development is supported by the Company’s scientific and regulatory experience in moving more than 100 drug products from discovery to clinical development and commercialization.
About BIOtech Japan 2017 (http://www.bio-t.jp/en/)
BIOtech Japan 2017 will be co-held with the newly launching show, BioPharma Expo 2017.
It will also be co-held with INTERPHEX JAPAN, Japan’s largest pharma manufacturing show and in-PHARMA JAPAN, a pharmaceutical ingredients show. Held altogether, it will gather representatives from the entire pharma industry under one roof.
Vice President Business Development
Rosenberg Business Communications